FY2025 Earnings Forecast for LRMR Issued By Lifesci Capital

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities researchers at Lifesci Capital issued their FY2025 EPS estimates for Larimar Therapeutics in a research report issued to clients and investors on Tuesday, February 24th. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings per share of ($1.70) for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q4 2025 earnings at ($0.41) EPS.

Other equities research analysts have also issued research reports about the stock. Citigroup raised their price target on shares of Larimar Therapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Larimar Therapeutics in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, January 22nd. Finally, Leerink Partners upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $16.14.

Larimar Therapeutics Price Performance

Shares of LRMR opened at $5.52 on Thursday. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.42. The stock has a 50 day simple moving average of $3.53 and a two-hundred day simple moving average of $3.79. The firm has a market cap of $456.95 million, a P/E ratio of -2.86 and a beta of 1.00.

Institutional Trading of Larimar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Deerfield Management Company L.P. raised its holdings in Larimar Therapeutics by 44.2% in the 3rd quarter. Deerfield Management Company L.P. now owns 30,606,974 shares of the company’s stock worth $98,861,000 after acquiring an additional 9,375,000 shares during the last quarter. Opaleye Management Inc. boosted its stake in Larimar Therapeutics by 114.7% during the 2nd quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company’s stock valued at $11,878,000 after purchasing an additional 2,195,923 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Larimar Therapeutics by 160.6% in the 3rd quarter. Woodline Partners LP now owns 1,622,850 shares of the company’s stock worth $5,242,000 after purchasing an additional 1,000,168 shares in the last quarter. AIGH Capital Management LLC purchased a new position in shares of Larimar Therapeutics in the third quarter worth $3,230,000. Finally, Blue Owl Capital Holdings LP raised its stake in shares of Larimar Therapeutics by 16.6% in the fourth quarter. Blue Owl Capital Holdings LP now owns 6,823,690 shares of the company’s stock worth $25,998,000 after purchasing an additional 970,650 shares during the last quarter. 91.92% of the stock is owned by hedge funds and other institutional investors.

More Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: Lifesci Capital upgraded LRMR to a “Strong-Buy” and published Q4 2025 and FY2025 EPS estimates (Q4: ($0.41); FY2025: ($1.70)), signaling analyst confidence in the company’s outlook and supporting demand for the shares. MarketBeat Lifesci Note
• Positive Sentiment: Citigroup raised its price target to $14 (buy), and Wedbush reaffirmed an outperform rating with an $11 target — both represent substantial upside vs. the current level and underpin bullish analyst sentiment. Benzinga
• Positive Sentiment: Unusually large call-option activity occurred (several thousand calls bought), suggesting short-term bullish positioning by traders and contributing to intraday spikes before the equity raise announcement. (No direct article link provided)
• Positive Sentiment: Coverage and commentary explaining the intraday rally were published (coverage noted a ~22% intraday rise before the selloff), which can attract momentum buyers and increased attention. AAII Article
• Neutral Sentiment: The company initially announced a proposed $75M underwritten offering (preliminary press release) — this first filing signaled capital raise intent before the deal was upsized. GlobeNewswire – Proposed Offering
• Negative Sentiment: Larimar priced an upsized underwritten public offering of 20,000,000 shares at $5.00 per share (gross proceeds ~$100M) and granted a 30-day option for an additional 3,000,000 shares — direct dilution and increased share supply are the main catalysts pressuring the stock. GlobeNewswire – Priced Offering

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.